Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective Evaluation of Cognitive Health and Related Factors in Elderly at Risk for Developing Alzheimer's Dementia: A Longitudinal Cohort Study.
Udeh-Momoh C, Price G, Ropacki MT, Ketter N, Andrews T, Arrighi HM, Brashear HR, Robb C, Bassil DT, Cohn M, Curry LK, Su B, Perera D, Giannakopoulou P, Car J, Ward HA, Perneczky R, Novak G, Middleton L. Udeh-Momoh C, et al. Among authors: brashear hr. J Prev Alzheimers Dis. 2019;6(4):256-266. doi: 10.14283/jpad.2019.31. J Prev Alzheimers Dis. 2019. PMID: 31686098
Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
Arrighi HM, Barakos J, Barkhof F, Tampieri D, Jack C Jr, Melançon D, Morris K, Ketter N, Liu E, Brashear HR. Arrighi HM, et al. Among authors: brashear hr. J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):106-12. doi: 10.1136/jnnp-2014-309493. Epub 2015 Feb 10. J Neurol Neurosurg Psychiatry. 2016. PMID: 25669746 Free PMC article.
Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.
Novak G, Fox N, Clegg S, Nielsen C, Einstein S, Lu Y, Tudor IC, Gregg K, Di J, Collins P, Wyman BT, Yuen E, Grundman M, Brashear HR, Liu E. Novak G, et al. Among authors: brashear hr. J Alzheimers Dis. 2016;49(4):1123-34. doi: 10.3233/JAD-150448. J Alzheimers Dis. 2016. PMID: 26639957 Clinical Trial.
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.
Brody M, Liu E, Di J, Lu M, Margolin RA, Werth JL, Booth K, Shadman A, Brashear HR, Novak G. Brody M, et al. Among authors: brashear hr. J Alzheimers Dis. 2016 Oct 18;54(4):1509-1519. doi: 10.3233/JAD-160369. J Alzheimers Dis. 2016. PMID: 27589523 Clinical Trial.
Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study.
Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM. Hager K, et al. Among authors: brashear hr. Alzheimers Res Ther. 2016 Nov 15;8(1):47. doi: 10.1186/s13195-016-0214-x. Alzheimers Res Ther. 2016. PMID: 27846868 Free PMC article. Clinical Trial.
A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease.
Ketter N, Liu E, Di J, Honig LS, Lu M, Novak G, Werth J, LePrince Leterme G, Shadman A, Brashear HR. Ketter N, et al. Among authors: brashear hr. J Prev Alzheimers Dis. 2016;3(4):192-201. doi: 10.14283/jpad.2016.118. J Prev Alzheimers Dis. 2016. PMID: 29199321
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, Einstein S, Booth K, Ketter N, Brashear HR; ELN115727-301/302 Investigator Group. Liu E, et al. Among authors: brashear hr. Neurology. 2018 Mar 6;90(10):e877-e886. doi: 10.1212/WNL.0000000000005060. Epub 2018 Feb 2. Neurology. 2018. PMID: 29429971 Clinical Trial.
101 results